DT Equipment (DTE) announces the appointment of Diego Areces as Chief Commercial Officer
16.2.2021 09:00:00 EET | Business Wire | Press release
DT Equipment ehf. (DTE) (www.dtequipment.com), a leader in real-time intelligence from liquid metals and developer of next-generation analytics for metals production and processing, is pleased to announce the appointment of Mr. Diego Areces as Chief Commercial Officer (CCO). His hire marks the latest in a series of appointments designed to further strengthen the DTE executive team and ensure that the company has the strategic, commercial and technical capabilities required for the next stage of its growth.
Commenting on the new appointment, Karl Matthiasson, CEO of DTE said, “I am very pleased to welcome Diego to our expanding executive team. His vast industry knowledge and extensive commercial experience will be indispensable, and we are delighted to have him on board as we continue the next stage of our journey.”
Mr. Areces who has 25 years’ experience in the industrial automation field, joins DTE to lead its commercial activities after a long tenure at Schneider Electric, where he held the position of Industrial Automation Networks Leader, Mining, Minerals, and Metals President and Process Automation North Asia Hub Leader, responsible for driving growth, transformation, and innovation. He will focus on bringing DTE’s breakthrough innovations in the metals analytics field to market and developing strategic relationships with customers and significant stakeholders.
“I am thrilled to join DTE, a great team of talented professionals on its way to transform a whole industry thanks to its breakthrough innovation", added Mr. Areces, “It is clear from my decades of working in the metals processing field that DTE’s real-time analytics and intelligence capabilities represent a significant breakthrough which offers a genuine opportunity to transform the way producers operate. I am focused on maximizing growth, value, sustainability, safety, and efficiency for all stakeholders, developing strategic relationships, and deploying business-driven technology and innovation; I look forward to an exciting new phase where there are no limits to what we can accomplish.
Mr. Areces is one of the early precursors of Industry 4.0, leading the deployment of internet technologies in industrial devices during the early 2000s. He has been a safety and sustainability champion and a significant contributor to the digital transformation of global industrial customers.
Mr. Areces is a founding member of modbus.org, was a marketing chair of the Interface for Distributed Automation (IDA) organization and a member of the Development Partner Institute for Mining. He holds an MS in Electronic Engineering from the University of Buenos Aires, Argentina, and a CSS in Administration and Management from Harvard University, US.
Find out more about DTE’s real-time liquid metals intelligence solutions at www.dtequipment.com
###
About DT Equipment
DTE, based in Reykjavik, Iceland, is a leading innovator in the field of real-time intelligence from liquid metals, helping customers to maximize value, efficiency, safety and sustainability. DTE’s vision is to transform metals production and processing with next-generation sensors and analytics, driving digital transformation of the metals industry towards Industry 4.0, while contributing to the 1.5-degree challenge.
DTE’s solution range combines first-in-industry LP-LIBS™ (Liquid-Phase Laser-Induced Breakdown Spectroscopy) elemental analysis with a powerful machine learning cloud platform, delivering valuable intelligence and predictive insights from liquid metals across the entire value chain.
For more information, please visit www.dtequipment.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210215005203/en/
Contact information
Contact Information
DT Equipment ehf.
Arleyni 8, 112 Reykjavik, Iceland
Karl Matthiasson
CEO
karl@dtequipment.com
Tel: (+354) 617 1326
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 11:22:00 EET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f
Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom